Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III Buys 6,266 Shares

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III bought 6,266 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were bought at an average price of $3.64 per share, with a total value of $22,808.24. Following the completion of the purchase, the director now owns 430,058 shares in the company, valued at approximately $1,565,411.12. The trade was a 1.48 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Perspective Therapeutics Trading Down 3.4 %

Perspective Therapeutics stock traded down $0.15 during trading hours on Wednesday, reaching $4.25. 649,499 shares of the company’s stock traded hands, compared to its average volume of 830,402. Perspective Therapeutics, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $19.05. The business’s 50 day moving average price is $11.15.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. Research analysts forecast that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently modified their holdings of CATX. nVerses Capital LLC bought a new stake in Perspective Therapeutics during the 3rd quarter worth approximately $57,000. US Bancorp DE grew its stake in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after acquiring an additional 3,866 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd bought a new position in shares of Perspective Therapeutics during the 2nd quarter worth approximately $118,000. Finally, Intech Investment Management LLC bought a new position in shares of Perspective Therapeutics during the 3rd quarter worth approximately $137,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Oppenheimer cut their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Truist Financial began coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Royal Bank of Canada lowered their price target on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $24.00 to $5.00 in a report on Monday. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.